Head-To-Head Comparison: Surrozen (SRZN) & Its Rivals

Surrozen (NASDAQ:SRZN) is one of 847 public companies in the “Biotechnology” industry, but how does it compare to its rivals? We will compare Surrozen to related businesses based on the strength of its dividends, analyst recommendations, profitability, risk, earnings, valuation and institutional ownership.

Earnings and Valuation

This table compares Surrozen and its rivals top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Surrozen	$11.51 million	-$242.03 million	-0.73
Surrozen Competitors	$695.89 million	$9.64 million	-10.06

Surrozen’s rivals have higher revenue and earnings than Surrozen. Surrozen is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Profitability

This table compares Surrozen and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Surrozen	-2,885.33%	N/A	-93.62%
Surrozen Competitors	-9,046.42%	-198.98%	-30.68%

Insider and Institutional Ownership

66.6% of Surrozen shares are held by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are held by institutional investors. 31.7% of Surrozen shares are held by company insiders. Comparatively, 13.0% of shares of all “Biotechnology” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Surrozen and its rivals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Surrozen	1	1	4	1	2.71
Surrozen Competitors	9772	15006	45333	1579	2.54

Surrozen presently has a consensus price target of $48.33, indicating a potential upside of 63.21%. As a group, “Biotechnology” companies have a potential upside of 96.05%. Given Surrozen’s rivals higher probable upside, analysts clearly believe Surrozen has less favorable growth aspects than its rivals.

Risk and Volatility

Surrozen has a beta of 0.47, indicating that its stock price is 53% less volatile than the S&P 500. Comparatively, Surrozen’s rivals have a beta of 1.07, indicating that their average stock price is 7% more volatile than the S&P 500.

Summary

Surrozen beats its rivals on 7 of the 13 factors compared.

Surrozen Company Profile

Surrozen, Inc., a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043, a hepatocyte-specific R-spondin mimetic bispecific fusion protein, which is in Phase 1b clinical trial for the treatment of severe liver diseases, including alcohol-associated hepatitis. The company develops SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies. Surrozen, Inc. is based in South San Francisco, California.